Allergic Asthma Clinical Trial
Official title:
A Double-blind, Placebo-controlled, Randomised, Parallel Group, Phase IIa Study to Investigate the Efficacy, Tolerability and Safety of 8 Doses of AZD8848 Administered Intranasally Once Weekly in Mild to Moderate Allergic Asthma Subjects Challenged With an Inhaled Allergen.
AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total. The first part will investigate the tolerability and safety of AZD8848 while the second part will investigate both the therapeutic effect of AZD8848 and how well patients tolerate the drug.
Status | Completed |
Enrollment | 60 |
Est. completion date | December 2011 |
Est. primary completion date | February 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - FEV1 > 70 % of predicted normal pre-bronchodilator - Documented history of asthma - Presence of allergic sensitivity Exclusion Criteria: - Clinically relevant disease and/or abnormality (past or present), which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results of the study, or the patient's ability to participate in the study. - Symptomatic allergic rhinitis - Any clinical relevant abnormal findings in physical examination or assessment which may put the patient at risk because of participation in the study |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Research Site | London | |
United Kingdom | Research Site | Manchester |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | FEV1, Late Asthmatic Response (LAR) - Pre-treatment | Forced Expiratory Volume in 1 second (FEV1), Late Asthmatic Response (LAR), is derived as the ratio of FEV1 Area Under Curve 4-10 hour post allergen challenge (AUC 4-10h) (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement. | Pre-treatment (Baseline measurement) | No |
Primary | FEV1, Late Asthmatic Response (LAR) - 1 Week After Last Dose | FEV1, Late Asthmatic Response (LAR), is derived as the ratio of FEV1 AUC 4-10h (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement. | 1 week after last dose | No |
Primary | FEV1, Late Asthmatic Response (LAR) - 4 Weeks After Last Dose | FEV1, Late Asthmatic Response (LAR), is derived as the ratio of FEV1 AUC 4-10h (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement. | 4 weeks after last dose | No |
Secondary | FEV1, Early Asthmatic Response (EAR) - Pre-treatment | FEV1, Early Asthmatic Response (EAR), is derived as the ratio of FEV1 Area Under Curve 0-2 hour post allergen challenge (AUC 0-2h) (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement. | Pre-treatment (Baseline measurement) | No |
Secondary | FEV1, Early Asthmatic Response (EAR) - 1 Week After Last Dose | FEV1, Early Asthmatic Response (EAR), is derived as the ratio of FEV1 AUC 0-2h (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement. | 1 week after last dose | No |
Secondary | FEV1, Early Asthmatic Response (EAR) - 4 Weeks After Last Dose | FEV1, Early Asthmatic Response (EAR), is derived as the ratio of FEV1 AUC 0-2h (computed using the trapezoidal formula divided by time) and the pre-challenge FEV1 measurement. | 4 weeks after last dose | No |
Secondary | PC20 Methacholine Challenge - Pre-treatment, Pre Allergen Challenge | PC20 is the provocation concentration of Methacholine causing a 20% fall in FEV1 | Pre-treatment, pre allergen challenge | No |
Secondary | PC20 Methacholine Challenge - Pre-treatment, Post Allergen Challenge | PC20 is the provocation concentration of Methacholine causing a 20% fall in FEV1 | Pre-treatment, post allergen challenge | No |
Secondary | PC20 Methacholine Challenge - 1 Week After Last Dose, Pre Allergen Challenge | PC20 is the provocation concentration of Methacholine causing a 20% fall in FEV1 | 1 week after last dose, pre allergen challenge | No |
Secondary | PC20 Methacholine Challenge - 1 Week After Last Dose, Post Allergen Challenge | PC20 is the provocation concentration of Methacholine causing a 20% fall in FEV1 | 1 week after last dose, post allergen challenge | No |
Secondary | PC20 Methacholine Challenge - 4 Weeks After Last Dose, Pre Allergen Challenge | PC20 is the provocation concentration of Methacholine causing a 20% fall in FEV1 | 4 weeks after last dose, pre allergen challenge | No |
Secondary | PC20 Methacholine Challenge - 4 Weeks After Last Dose, Post Allergen Challenge | PC20 is the provocation concentration of Methacholine causing a 20% fall in FEV1 | 4 weeks after last dose, post allergen challenge | No |
Secondary | Sputum Cellularity and Cytokines, Tumour Necrosis Factor Alpha (TNFa) - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, TNFa - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, TNFa - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, TNFa - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, TNFa - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, TNFa - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Interleukin-1ß (IL-1ß) - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-1ß - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-1ß - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-1ß - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-1ß - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-1ß - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Interleukin-5 (IL-5) - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-5 - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-5 - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-5 - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-5 - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-5 - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Interleukin-6 (IL-6) - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-6 - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-6 - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-6 - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-6 - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-6 - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Interleukin-8 (IL-8) - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-8 - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-8 - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-8 - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-8 - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-8 - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Interleukin-10 (IL-10) - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-10 - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-10 - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-10 - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-10 - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-10 - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Interleukin-13 (IL-13) - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-13 - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-13 - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-13 - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-13 - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, IL-13 - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Total Cells/g - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Total Cells/g - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Total Cells/g - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Total Cells/g - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Total Cells/g - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Total Cells/g - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Eosinophils - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Eosinophils - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Eosinophils - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Eosinophils - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Eosinophils - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Eosinophils - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Neutrophils - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Neutrophils - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Neutrophils - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Neutrophils - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Neutrophils - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Neutrophils - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Macrophages - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Macrophages - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Macrophages - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Macrophages - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Macrophages - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Macrophages - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Lymphocytes - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Lymphocytes - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Lymphocytes - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Lymphocytes - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Lymphocytes - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Lymphocytes - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Epithelial Cells - Pre-treatment, Pre Allergen Challenge | Pre-treatment, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Epithelial Cells - Pre-treatment, Post Allergen Challenge | Pre-treatment, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Epithelial Cells - 1 Week After Last Dose, Pre Allergen Challenge | 1 week after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Epithelial Cells - 1 Week After Last Dose, Post Allergen Challenge | 1 week after last dose, post allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Epithelial Cells - 4 Weeks After Last Dose, Pre Allergen Challenge | 4 weeks after last dose, pre allergen challenge | No | |
Secondary | Sputum Cellularity and Cytokines, Epithelial Cells - 4 Weeks After Last Dose, Post Allergen Challenge | 4 weeks after last dose, post allergen challenge | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03850626 -
Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
|
||
Completed |
NCT02911688 -
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure
|
Phase 2 | |
Active, not recruiting |
NCT01776177 -
The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy
|
N/A | |
Completed |
NCT00485576 -
Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
|
Phase 2 | |
Completed |
NCT00515775 -
Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children
|
N/A | |
Completed |
NCT00736801 -
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
|
N/A | |
Completed |
NCT04259164 -
Anti-inflammatory Effects Glycopyrronium
|
Phase 3 | |
Active, not recruiting |
NCT04619017 -
Airway Immune Response to Allergens (Use Lay Language Here)
|
Phase 1 | |
Completed |
NCT01699594 -
Change in Airway Responsiveness After Allergen Exposure
|
N/A | |
Completed |
NCT01353755 -
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
|
Phase 3 | |
Completed |
NCT00434434 -
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
|
Phase 2 | |
Completed |
NCT00492076 -
Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma
|
Phase 4 | |
Completed |
NCT00490425 -
Prevention of Asthma and Allergy by Probiotic Lactobacillus GG
|
Phase 4 | |
Completed |
NCT00829179 -
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
|
Phase 3 | |
Recruiting |
NCT04542902 -
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma
|
N/A | |
Recruiting |
NCT04109534 -
Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma
|
N/A | |
Active, not recruiting |
NCT05186025 -
Tyrosine Allergoid Paediatric and Adult Study
|
||
Withdrawn |
NCT03307278 -
House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance
|
N/A | |
Enrolling by invitation |
NCT06151938 -
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
|
||
Withdrawn |
NCT04401631 -
Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation
|